Greenwich LifeSciences accelerates patient screening in FLAMINGO-01 clinical trial

Greenwich LifeSciences accelerates patient screening in FLAMINGO-01 clinical trial
Greenwich LifeSciences boosts screening

Greenwich LifeSciences announces an increase in the patient screening rate for its ongoing FLAMINGO-01 clinical trial.

The company is advancing the enrollment phase, as reflected in the expanded screening activity. The FLAMINGO-01 study is a key part of Greenwich LifeSciences' development efforts in oncology. The latest update highlights strengthened operational momentum as the trial progresses toward its next milestones. Further details on the impact of the increased screen rate have not yet been disclosed.

This material may contain third-party opinions, none of the data and information on this webpage constitutes investment advice according to our Disclaimer. While we adhere to strict Editorial Integrity, this post may contain references to products from our partners.
Weekly Top Bonuses
up to $2,500
deposit bonus for all clients
CLAIM BONUS
Your capital is at risk.